| | 
Part, Chapter, Paragraph
1 I, 3. 4 | Henkens, A. Liefbroer & H. Moors (2001), Meningen
2 II, 4. 3 | Montpellier, EHEMU.~ ~Kung, H., D. Hoyert, et al. (2007):
3 II, 4. 3 | Services: 34.~ ~Van Oyen, H., J. van der Heyden, et
4 II, 5. 2. 6 | B, Maheshwari N, Schrott H (2005). Pleiotropic effects
5 II, 5. 2. 7 | 07.07).~Evans A, Tolonen H, Hense HW, Ferrario M, Sans
6 II, 5. 2. 7 | 167:573-579.~Kesteloot H, Sans S, and Kromhout D (
7 II, 5. 2. 7 | Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortman S, Sans
8 II, 5. 2. 7 | Fortman S, Sans S, Tolonen H, Evans A, Ferrario M, Tuomilehto
9 II, 5. 2. 7 | 3-10.~Sans S, Kesteloot H, Kromhout D on behalf of
10 II, 5. 2. 7 | Sarti C, Stegmayr B, Tolonen H, MAhonen M, Tuomilehto J,
11 II, 5. 2. 7 | Epidemiol14: 510-20.~Tolonen H, Mahonen M, Asplund K, rastenyte
12 II, 5. 2. 7 | 2367-2375.~Tunstall-Pedoe H, Kuulasmaa K, Mahonen M,
13 II, 5. 2. 7 | Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P (
14 II, 5. 2. 7 | 1547-57.~Tunstall-Pedoe H, Vanuzzo D, Hobbs M et al
15 II, 5. 3. 9 | Boyle P, Autier P, Bartelink H, et al (2003): European
16 II, 5. 3. 9 | Estève J, Sant M, Storm H, Allemani C, Ciccolallo
17 II, 5. 3. 9 | 3751.~ ~Hakama M, De Koning H (2007): Portuguese Presidency
18 II, 5. 3. 9 | Hédelin G, Matsuda T, Moller H, Moller T, Verdecchia A,
19 II, 5. 3. 9 | A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone
20 II, 5. 5.Int(15)| Kivela S-L, Lobo A, Magnusson H, Mann AH, Meller I, Prince
21 II, 5. 5. 1 | Bruffaerts R, Brugha TS, Bryson H (2004a). Prevalence of mental
22 II, 5. 5. 3 | Disorder 41:1 92-95.~Hoek H W, van Hoeken D, (2003):
23 II, 5. 5. 3 | J, Issakidis C, Lapsley H (2003): Cost-effectiveness
24 II, 5. 5. 3 | 427-435.~Baumann A, Zäske H, Decker P, Klosterkötter
25 II, 5. 5. 3 | Ono Y, Takeshima T, Uda H, Karam EG, Fayyad JA, Karam
26 II, 5. 5. 3 | Anderson P eds.).~Fang H, Rizzo JA (2007): Do psychiatrists
27 II, 5. 5. 3 | Gaebel W, Zäske H, Baumann AE, Klosterkötter
28 II, 5. 5. 3 | Research 3(1-2):23-33.~Häfner H and Maurer K (2006): Early
29 II, 5. 5. 3 | Psychiatry 5(3):130-8.~Häfner H, Maurer K, Ruhrmann S, Bechdolf
30 II, 5. 5. 3 | Fleischhacker W, Boter H, Davidson M, Vergouwe Y,
31 II, 5. 5. 3 | Hambrecht M, VON Reventlow H (2005): The European Prediction
32 II, 5. 5. 3 | Michels R, Malchow CP, Dilling H (2002): Comparison of psychiatric
33 II, 5. 5. 3 | L, Werdelin G, Karlsson H, Bjarnason O, Bengtsson-Tops
34 II, 5. 5. 3 | W, Buchkremer G, Häfner H, Klosterkötter J, Maier
35 II, 5. 5. 3 | 2007.~Wrigley S, Jackson H, Judd F, Komiti A (2005):
36 II, 5. 5. 3 | Epilepsia 43:1402-1409.~Lindsten H, Nystrom L, Forsgren L (
37 II, 5. 5. 3 | Psychiatry 71:632-637.~Lindsen, H, Stenlund, H, Forsgren L (
38 II, 5. 5. 3 | 637.~Lindsen, H, Stenlund, H, Forsgren L (2001): Remission
39 II, 5. 5. 3 | PE, Blom BH, Skeidsvoll H, Mykletun A (2000): Prevalence,
40 II, 5. 5. 3 | 219-230.~Brønnum-Hansen H, Koch-Henriksen N, Hyllested
41 II, 5. 5. 3 | 1901–1907.~Brønnum-Hansen H, Koch-Henriksen N, Stenager
42 II, 5. 5. 3 | 844-850.~Brønnum-Hansen H, Stenager E, Hansen T, Koch-Henriksen
43 II, 5. 5. 3 | Hansen T, Koch-Henriksen H (2006): Survival and mortality
44 II, 5. 5. 3 | Aarseth JH, Myhr KM, Nyland H, Midgard R (2004): Multiple
45 II, 5. 5. 3 | De Sã J, Paulos A, Mendes H, et al (2006): The prevalence
46 II, 5. 5. 3 | Koch-Henriksen N, Brønnum-Hansen H, Hyllested K (1992): Incidence
47 II, 5. 5. 3 | W, Rodriguez M, Lassmann H (1996): Distinct patterns
48 II, 5. 5. 3 | Grytten N, Aarseth JH, Nyland H (2006): The Norwegian Multiple
49 II, 5. 5. 3 | Pugliatti M, Rosati G, Carton H, et al (2006): The epidemiology
50 II, 5. 5. 3 | McFarland HF, Hohlfeld H (eds). Multiple sclerosis.
51 II, 5. 5. 3 | MB, Vlietnick R, Carton H (1994): Prevalence of multiple
52 II, 5. 5. 3 | 632.~Anderson C, Checkoway H, Franklin GM, Beresford
53 II, 5. 5. 3 | Poskanzer DC, Rolland C, Miller H (1966): Neurological disease
54 II, 5. 5. 3 | Bartalesi F, Gamboa Barahon H, Giuffrida S, Reggio A (
55 II, 5. 5. 3 | Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel
56 II, 5. 5. 3 | Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder
57 II, 5. 6. 6 | Martin-Mola E, Nielsen H, Silman A, Smolen J, Yazici
58 II, 5. 6. 6 | Silman A, Smolen J, Yazici H (2007): EULAR Recommendations
59 II, 5. 6. 6 | Schulenburg JM, Zeidler H, Ruof J (2005): Direct Costs
60 II, 5. 6. 6 | Miner Res 18:1139-1141~Merx H, Dreinhofer K, Schrader
61 II, 5. 6. 6 | Puhl W, Gunther KP, Brenner H (2003): International Variation
62 II, 5. 6. 6 | Palmer KT, Walsh K, Bendall H, Cooper C, Coggon D (2000)
63 II, 5. 6. 6 | Allison T, Brammah T, Busby H, Roxby M, Simmons A, Williams
64 II, 5. 6. 6 | 84-91~Woolf AD, Zeidler H, Haglund U, Carr AJ, Chaussade
65 II, 5. 7. 7 | Meisinger C, Doring A, Lowel H (2006): Chronic kidney disease
66 II, 5. 8. 7 | Dollerup J, Baekke Borgeskov H, Lange P (2007): The cost
67 II, 5. 8. 7 | Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J (
68 II, 5. 8. 7 | MW, Schellevis FG, Raat H (2006): Prevalence estimates
69 II, 5. 8. 7 | IL, Nissinen A, Tukiainen H, Koskela H (2006): Thirty-year
70 II, 5. 8. 7 | A, Tukiainen H, Koskela H (2006): Thirty-year cumulative
71 II, 5. 8. 7 | 2006; 130: 1129-1137.~ ~Rea H, McAuley S, Stewart A, Lamont
72 II, 5. 8. 7 | JB, Visick GT, Muellerova H, Payvandi N, Hansell AL (
73 II, 5. 8. 7 | Sunyer J, Zock JP, Kromhout H, Garcia-Esteban R, Radon
74 II, 5. 8. 7 | J, Kogevinas M, Kromhout H, Burney P, Antó Jm, and
75 II, 5. 9. 7 | Jan;42(1):60-5~ ~Schipper H, Clinch J, Olweny CLM (1990):
76 II, 5. 10. 7 | Strachan D, Ross Anderson H (2003): Increasing hospital
77 II, 5. 10. 7 | Mothes T, Troncone R, Wieser H (2001): Analysis and clinical
78 II, 5. 11. 3 | Source: Modified from H. Williams et al. Epidemiology
79 II, 5. 11. 3 | mean of hundreds of days (H Suzuki, 1998). For this
80 II, 5. 11. 3 | 130.~T Nakada, M Iijima, H Nakayama, HI Maibach, Role
81 II, 5. 11. 3 | TP Dang, C Macpherson, H Maibach, HI Maibach, Prevalence
82 II, 5. 11. 3 | Dermatitis, 1997;37(2):78-81.~H Suzuki, Nickel and gold
83 II, 5. 11. 7 | Fouere S, Adjadj L, Pawin H (2005): How patients experience
84 II, 5. 11. 7 | HC, Pembroke AC, Forsdyke H et al (1995): London-born
85 II, 5. 11. 7 | Medical Press 1997.~ ~Williams H, Svensson A, Diepgen Th,
86 II, 5. 14. 8 | Bourgeois D, Bratthal D, Ogawa H (2005): Oral health information
87 II, 5. 14. 8 | Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day S, N’Diaye
88 II, 8. 2. 1 | 53~Fujiura, G.T., Park, H. J. and Rutkowski-Kmitta,
89 II, 8. 2. 1 | 101-6.~Lennox N, Beange H, Davis R, et al. Management
90 II, 8. 2. 1 | 85-90~Ouellette-Kuntz, H., (2005). Understanding
91 II, 8. 2. 1 | 136, 903-012.~Prosser, H., Moss, S., Costello, H.,
92 II, 8. 2. 1 | H., Moss, S., Costello, H., Simpson, N., Patel, P., &
93 II, 8. 2. 1 | 42 (4), 264-272.~Rimmer,J.H. (1999). health promotion
94 II, 8. 2. 1 | Bradley,V., Buntinx, W.H.E., Coulter, D.L., Craig,
95 II, 8. 2. 1 | Wehmeyer, M.L. and Yeager, M.H. (2007). The Renaming of
96 II, 8. 2. 1 | Straetmans, J.M.J.A.A., H.M.J. van Schrojenstein Lantman-de
97 II, 8. 2. 1 | Schrojenstein Lantman-de Valk, H., Buono, S., Azema, B.,
98 II, 8. 2. 3 | available at: htt ~ ~Fortnum H, Davis A (1997): Epidemiology
99 II, 9 | subjects spent at least 3.5 h per week in physical activity,
100 II, 9. 1. 1 | 3-7.~ ~Breart G, Barros H, Wagener Y, Prati S (2003):
101 II, 9. 1. 1 | Usher RH, Kramer MS, Yang H, Morin L, Fretts RC (2000):
102 II, 9. 1. 1 | Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston
103 II, 9. 1. 1 | Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston
104 II, 9. 1. 1 | Kramer MS, Platt RW, Yang H, Haglund B, Cnattingius
105 II, 9. 1. 1 | Breart G, Alexander S, Barros H, Blondel B, et al (2003):
106 II, 9. 1. 2 | medicine during pregnancy.~ ~h) More research should be
107 II, 9. 1. 2 | References~ ~Abramsky L, Dolk H and a EUROCAT Folic Acid
108 II, 9. 1. 2 | N, de Vigan C, de Walle H, Erickson EJ, Halliday J,
109 II, 9. 1. 2 | 693-705.~Bréart G, Barros H, Wagener Y, Prati S (2003):
110 II, 9. 1. 2 | Busby A, Armstrong B, Dolk H, Armstrong N, Haeusler M,
111 II, 9. 1. 2 | Bianca S, Gatt M, de Walle H, Braz P, Latos-Bielenska
112 II, 9. 1. 2 | Busby A, Abramsky L, Dolk H, Armstrong B and a EUROCAT
113 II, 9. 1. 2 | Busby A, Ritvanen A, Dolk H, Armstrong N, De Walle H,
114 II, 9. 1. 2 | H, Armstrong N, De Walle H, Riano-Galan I, Gatt M,
115 II, 9. 1. 2 | F, Calzolari E, De Walle H, Knill-Jones R, Candela
116 II, 9. 1. 2 | Med 2007;357: 135-42.~Dolk H, Loane M, Garne E, de Walle,
117 II, 9. 1. 2 | Loane M, Garne E, de Walle, H, Queisser-LuftA, de Vigan
118 II, 9. 1. 2 | Gener B, Haeusler M, Jordan H, Tucker D, Stoll C, Feijoo
119 II, 9. 1. 2 | Vol 53, pp 2S87-2S95.~Dolk H, Vrijheid, Scott JES, Addor
120 II, 9. 1. 2 | B, de Vigan C, de Walle H, Garne E, Loane M, Pierini
121 II, 9. 1. 2 | No 3, pp 398-402.~Dolk H, Vrijheid M (2003): "The
122 II, 9. 1. 2 | Garne E, Loane M, Dolk H, de Vigan C, Scarano G,
123 II, 9. 1. 2 | 20:328-38.~Loane M, Dolk H, Bradbury and a EUROCAT
124 II, 9. 1. 2 | 131-7.~Schaefer C, Garbis H, McElhatton P, Reuvers M,
125 II, 9. 1. 2 | Elsevier 2001.~Vrijheid M, Dolk H, Stone D, Abramsky L, Alberman
126 II, 9. 3. 1 | Bergdahl S, Lodding P, Lilja H, Hugosson J (2007): Prostate
127 II, 9. 3. 1 | 54(5): 328-332~ ~Brown H (2003): Women's Lack of
128 II, 9. 3. 1 | practice, 62(6):973-6~ ~Lee H, McGovern K, Finkelstein
129 II, 9. 3. 2 | 3-7.~ ~Breart G, Barros H, Wagener Y, Prati S (2003):
130 II, 9. 3. 2 | Usher RH, Kramer MS, Yang H, Morin L, Fretts RC (2000):
131 II, 9. 3. 2 | Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston
132 II, 9. 3. 2 | Kramer MS, Platt RW, Yang H, Haglund B, Cnattingius
133 II, 9. 3. 2 | van Dongen P, van Geijn H, Bennebroek Gravenhorst
134 II, 9. 3. 2 | Breart G, Alexander S, Barros H, Blondel B, et al (2003):
135 II, 9. 3. 3 | Bloemenkamp KWM, Jahn A, Karro H, Olsen J, Temmerman M on
136 II, 9. 3. 3 | 1215-23.~Layte R, McGee H, Qual A, Rundle K, Cousins
137 II, 9. 4. 4 | subjects spent at least 3.5 h per week in physical activity,
138 II, 9. 4. 7 | Health in Europe.~ ~Jaleel H, Allan P S, Wade A A (1999):
139 II, 9. 5. 6 | Institute of Education~ ~Brown H (2003): Women's Lack of
140 II, 9. 5. 6 | 31 January~ ~Jernigan D H (2001): Global Status Report:
141 II, 9. 5. 6 | Organization, Geneva~ ~Jernigan D H (2001): Global Status Report:
142 III, 10. 1. 3 | J, Beaglehole R, Tanaka H.) New York, Oxford University
143 III, 10. 1. 3 | J, Beaglehole R, Tanaka H.) New York, Oxford University
144 III, 10. 1. 3 | J, Beaglehole R, Tanaka H.) New York, Oxford University
145 III, 10. 1. 3 | 174.~Kuntsche EN, Kuendig H (2006): What is worse? A
146 III, 10. 2. 1 | Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P,
147 III, 10. 2. 1 | Scully C, Siracka E, Storm H, Tubiana M, Tursz T, Veronesi
148 III, 10. 2. 1 | Zatonski W, zur Hausen H (2003): European Code Against
149 III, 10. 2. 1 | Morleo M, Stokes E, Sumnall H, Witty K, Bellis M (2007):
150 III, 10. 2. 1 | Drugs 20 25-40.~ ~Kristenson H, Osterling A, Nilsson JA,
151 III, 10. 2. 1 | Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day S, N’Diaye
152 III, 10. 2. 1 | S, Axelsson S, Dahlgren H, Holm AK, Kallestal C, Lagerlof
153 III, 10. 2. 1 | Steingrímsdóttir, L, Þorgeirsdóttir H, Ólafsdóttir AS~Ireland~
154 III, 10. 2. 1 | a two non-consecutive 24-h recalls (Brussard et al.,
155 III, 10. 2. 1 | Becker W, Enghardt-Barbieri H (2004): Svenska barns matvanor
156 III, 10. 2. 1 | in Swedish).~ ~Bendixen H, Holst C, Sørensen TIA,
157 III, 10. 2. 1 | Branca F, Nikogosian H, Lobstein T, eds (2007a):
158 III, 10. 2. 1 | Branca F, Nikogosian H, Lobstein T, eds (2007b):
159 III, 10. 2. 1 | A, Stamatakis E, Wardle H (2005): Obesity among children
160 III, 10. 2. 1 | Connell M, Yeh MC, Nawaz H, Njike V, Anderson LM, Cory
161 III, 10. 2. 1 | Gabhainn SN, Friel S, Corrigan H, Nolan G, Sixsmith J, Walsh
162 III, 10. 2. 1 | Kramer MS, Morin I, Yang H, Platt RW, Usher R, McNamara
163 III, 10. 2. 1 | Platt RW, Usher R, McNamara H, Joseph KS, Wen SW (2002):
164 III, 10. 2. 1 | Varga A, Domonkos A, Agoston H, Balázs A, Mozsáry E, Vitrai
165 III, 10. 2. 1 | Elmadfa I, Freisling H, König J et al. Austrian
166 III, 10. 2. 1 | Blachfelner J, Freisling H (ed.). 2nd Viennese Nutrition
167 III, 10. 2. 1 | Clavel-Chapelon F, Kesse E, Boeing H, Klipstein-Grobusch K, Trichopoulou
168 III, 10. 2. 1 | Thiebaut A, Miller AB, Boeing H, Kolyva M, Saieva C, Celentano
169 III, 10. 2. 4 | Brand A, Schröder P, Brand H, Zimmern R (2006): Getting
170 III, 10. 2. 4 | Johnson J, Cox N J, Wichmann H E, Wienker T F, Schulze
171 III, 10. 2. 4 | Schwarz P E, Lindner T H (2007): A German genome-wide
172 III, 10. 2. 4 | Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi
173 III, 10. 2. 4 | Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi
174 III, 10. 2. 5 | Luoma I, Salmelin R, Davis H, Tsiantis J, Ispanovic-Radojkovic
175 III, 10. 2. 5 | 181-91.~ ~Puura K, Davis H, Papadopoulou K, Tsiantis
176 III, 10. 3. 1 | Sweden, (ww e)~Boegli, H., 2006. Risk assessment
177 III, 10. 3. 1 | Barros-Dios JM, Baysson H, Bochicchio F, Deo H, Falk
178 III, 10. 3. 1 | Baysson H, Bochicchio F, Deo H, Falk R, Forastiere F, Hakama
179 III, 10. 3. 1 | Kempen EEMM van, Kruize H, Boshuizen HC, Ameling CB,
180 III, 10. 3. 1 | 2006) Prüss-Üstün A, Zeeb H, Mathers C, RepacholiM (
181 III, 10. 3. 2 | et al. (2004).~ ~Barton, H.A. et al. (2005): Assessing
182 III, 10. 3. 2 | R, Ostermann, B, Mielke, H. (2005): Rückstände von
183 III, 10. 4. 2 | Y, Kishi, R, Nakazawa, H.(2004). Perfluorooctane
184 III, 10. 5. 1 | exceed the recommended 24-h limit value of 50 microgram/
185 III, 10. 5. 1 | Article. Research Support, N.I.H., Extramural. Research Support,
186 III, 10. 5. 1 | publication No. 2/2006).~Frumkin H (2003): Healthy places:
187 III, 10. 5. 1 | 1451-1456.~Kim HS, Mccarthy H, Oren R, Finzi C, EllsWorth
188 III, 10. 5. 2 | Health 52:487-493.~ ~Völzke H et al. (2006): Urban-rural
189 III, 10. 5. 3 | Boedeker W, Klindworth H (2007): Hearts and minds
190 III, 10. 6. 1 | Börsch-Supan A, Jürges H. (2005). The Survey of Health,
191 III, 10. 6. 1 | 1985.~ ~Kohb M, Künemund H, Lüdicke J. (2005): Family
192 III, 10. 6. 2 | JJM, Lahelma E, Van Oyen H, Rasmussen NK, Regidor E,
193 IV, 11. 6. 5 | Bartholomee Y, Maarse H (2006): "Health insurance
194 IV, 11. 6. 5 | 295.~ ~Bunker J, Frazier H et al. (1994): "Improving
195 IV, 11. 6. 5 | 189-206.~ ~Glennerster H (1997): Paying for Welfare:
196 IV, 11. 6. 5 | Vaughan, J.P., Morrow, R.H. Manual of Epidemiology
197 IV, 12. 2 | Type 2 diabetes a key healt h priority during its Presidency
|
|
| |
